BIVALIRUDIN

Bivalirudin received initial approval from the United States Food and Drug Administration (FDA) on 15 December 2000.

Bivalirudin is primarily used as an anticoagulant in medical procedures. Its main uses include preventing blood clot formation during percutaneous coronary intervention (PCI) procedures, managing heparin-induced thrombocytopenia (HIT), serving as an alternative anticoagulant when heparin is contraindicated, and as part of anticoagulation strategies in certain cardiac surgeries. These applications help maintain blood flow, prevent clot formation, and manage thrombotic disorders in specific clinical contexts.

Bivalirudin is administered via the intravenous (IV) route. It is important to follow the dosing instructions provided on the product's packaging or as your healthcare provider recommends.

Bivalirudin can have side effects. Common side effects include bleeding, which can range from minor oozing or bruising to more severe bleeding events. Pain at the injection site and headaches are also commonly reported. Additionally, there is a risk of allergic reactions, although they are rare, and they can manifest with symptoms like difficulty breathing, swelling of the face or throat, hives, or a rapid heartbeat.

Bivalirudin significantly increases the risk of bleeding, which can be minor or major. Although rare, allergic reactions to bivalirudin can occur. It can cause a decrease in platelet count, which may lead to thrombocytopenia. It can potentially overdose, which can result in severe bleeding complications.

Patients need close monitoring for signs of bleeding, such as easy bruising, uncontrolled bleeding, or blood in urine or stool after taking Bivalirudin. If any of the allergic reactions occur, immediate medical attention is necessary. Patients require regular monitoring of platelet levels, especially in patients at higher risk, and consider alternative anticoagulant strategies if significant thrombocytopenia develops.

Bivalirudin carries an increased bleeding risk requiring careful monitoring, particularly in patients with renal impairment who may require dose adjustment. Hepatic function is minimally affected; however, severe liver disease warrants monitoring. Screen for heparin allergy and apply appropriate dosing and monitoring protocols to prevent thrombotic events. Monitor for potential drug interactions and be prepared to manage allergic reactions. Use during pregnancy or breastfeeding only when potential benefits justify the risks. Paediatric use has limited safety data available. Elderly patients may need additional monitoring. Patients should exercise caution with alcohol consumption and avoid driving or operating heavy machinery if dizziness or other adverse effects occur.

KD Tripathi, Essentials of Medical Pharmacology, Drugs affecting coagulation, bleeding and thrombosis, 7th edition, 2013, 617, 620. Medicines company, US Food and Drug Administration, [ Revised on March 2016], [ Accessed on April 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020873s036lbl.pdf Accord Healthcare, Electronics Medicine compendium (EMC), [ Revised on May 2016], [ Accessed on 27th Sept 2023], https://www.medicines.org.uk/emc/files/pil.7229.pdf